Gebasaxturev by Merck for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Gebasaxturev is under clinical development by Merck and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData, Phase II drugs for Oral Cavity (Mouth) Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Gebasaxturev LoA Report. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.Gebasaxturev overviewCavatak (Coxsackievirus A21, CVA-21) is under development for the treatment of colorectal cancer, metastatic uveal melanoma, solid tumors, head and neck cancer, triple-negative breast cancer, advanced or metastatic head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma, hepatocellular carcinoma, metastatic gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, chronic lymphocytic leukemia, acute myeloid leukemia, prostate cancer, pancreatic cancer, metastatic melanoma and bladder cancer. It was also under development for the treatment of glioma, mesothelioma, breast cancer, non-muscle invasive bladder cancer, metastatic castrate-resistant prostate cancer, non-small cell lung cancer and multiple myeloma. Coxsackievirus A21 is administered through intratumoral, intravesical and intravenous route. Cavatak is the formulation of the Coxsackievirus Type A21 (CVA21). Coxsackievirus A21 acts via ICAM-1 targeted virotherapy which delays or avoids the impact of virus neutralization. The drug candidate is developed using oncolytic virotherapy technology.Merck overviewMerck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US. For a complete picture of Gebasaxturev's drug-specific PTSR and LoA scores, buy the report here.
Gebasaxturevis under clinical development by Merck and currently in Phase II for Oral Cavity (Mouth) Cancer.
What's Your Reaction?
